Introduction and Clinical Rationale

Poor medication adherence and incorrect inhaler technique represent significant hurdles, affecting 30 to 70% of pediatric asthma patients globally and in India.
Uncontrolled asthma due to non-adherence leads to frequent exacerbations, school absenteeism, hospitalizations, and oral corticosteroid overuse.
Traditional monitoring methods, such as self-reporting and pharmacy refill checks, overestimate actual adherence by 20 to 40%.
Electronic monitoring devices bridge this objective data gap, preventing delayed interventions and unnecessary medication escalation.

Device Typology and Core Features

The technology encompasses sensor-equipped metered-dose inhalers (MDIs), dry-powder inhalers (DPIs) with Bluetooth connectivity (e.g., Propeller Health, Adherium SmartTrack), smart spacers, and smart nebulizers.

Technological Feature	Clinical Utility
Audio-visual reminders	Directly improves routine controller medication compliance through alerts.
Flow sensors	Measures inhalation flow and volume while providing real-time technique coaching.
Geofencing capabilities	Identifies specific environmental triggers through location tracking.
Clinician dashboards	Facilitates shared decision-making and early detection of rescue medication overuse, which predicts impending exacerbations.

A 2025 comprehensive review demonstrated that audio-visual reminder-enabled smart inhalers boosted preventer adherence to 84% compared to 30% in post-emergency department pediatric cohorts.
Real-world studies from 2025 to 2026 show sustained asthma control, 39% fewer rescue medication uses, and significantly reduced hospitalizations.
Global meta-analyses link digital tools to a 10 to 15% additional adherence gain when combined with clinician feedback, resulting in measured improvements in FEV1 and quality of life.
Pediatric safety data is favorable, though device durability is an issue, with breakage rates reaching 37 to 50% in some feedback-enabled trials.

GINA 2025 strongly emphasizes objective adherence assessment as a core component of evaluating uncontrolled asthma.
Digital tools are recommended as adjuncts to guide step-down therapy in SMART (single maintenance and reliever therapy) protocols and must be utilized to reassess adherence before escalating a child to biologics.
The Indian Academy of Pediatrics endorses digital tools for refractory cases, technique training, and advocates for their integration into school health programs.

The Ministry of Health and Family Welfare acknowledges these tools under the National Digital Health Mission.
While not currently procured under public programs, adherence data integration into platforms like U-WIN and IHIP is anticipated to support pollution-linked respiratory surveillance.

Pediatricians must assess baseline adherence, select age-appropriate connected devices (generally feasible for children >4 to 5 years), and integrate clinical dashboards for virtual follow-up.
They play a crucial role in counseling parents on early alert benefits and using device data for shared decisions regarding therapy escalation.

High device costs (₹5,000 to 20,000 per device), the rural-urban digital divide, and data privacy concerns limit equitable access in India.
Future directions point toward affordable indigenous sensors, artificial intelligence predictive analytics, and integration with wearables for real-time wheeze detection.